Propanc Biopharma Reports $6.36 Million Net Loss in Q3 Fiscal 2026

Propanc Biopharma, Inc. reported its financial results for the third quarter of fiscal year 2026, revealing a net loss of $6.36 million for the three months ending March 31, 2026, compared to a net loss of $54.07 million for the same period in the previous year. The company did not generate any revenue during this quarter, consistent with its performance in the prior year. For the nine months ended March 31, 2026, the net loss was $14.29 million, a significant reduction from the $54.85 million loss reported for the same period in 2025. The decrease in losses is attributed to a substantial reduction in operating expenses, which fell to $6.4 million from $53.1 million year-over-year.

The company’s total assets decreased to $14.33 million as of March 31, 2026, down from $19.63 million at the end of the previous fiscal year. This decline was primarily driven by a reduction in prepaid expenses and cash reserves, which increased to $443,702 from $12,088. Current liabilities also decreased to $3.48 million from $5.58 million, reflecting a decrease in accounts payable and accrued expenses. The company’s stockholders’ equity stood at $9.83 million, down from $13.91 million, largely due to the accumulated deficit increasing to $140.84 million.

In terms of operational developments, Propanc Biopharma has continued to focus on its lead product candidate, PRP, which is in the preclinical phase of development. The company has made strides in its patent portfolio, holding 84 granted or allowed patents and 7 provisional patents related to its cancer treatment technologies. The company has not reported any significant changes in customer counts or geographic expansion, as it remains primarily focused on product development and regulatory approvals.

The company’s cash flow from operating activities showed a net cash outflow of $4.08 million for the nine months ended March 31, 2026, compared to a smaller outflow of $312,982 in the same period last year. Financing activities provided $4.47 million in cash, primarily from the issuance of convertible promissory notes and common stock. The company’s management indicated that the financial results reflect ongoing efforts to streamline operations and reduce costs while advancing its product development initiatives.

Looking ahead, Propanc Biopharma aims to continue its focus on the development of PRP and expand its patent portfolio. The company anticipates that its strategic initiatives will position it for future growth as it seeks to establish a market presence for its cancer treatment technologies. However, the company has acknowledged that it may require additional financing to support its ongoing operations and development efforts.